The future of human health will be defined by technologies that accelerate the world's access to more effective medicines.
Human cells are a cornerstone of fundamental disease research, drug discovery, and clinical translation. Yet, despite decades of research into iPSCs, emerging cures for some of the world鈥檚 most pervasive diseases have been bottlenecked by a lack of access to standardised, easy to use and readily accessible human cells.
We built ioCells to solve this challenge.
Developed on our platform, and powered by opti-ox technology, ioCells are human cells deterministically programmed from iPSCs consistently, at scale. With ioCells, scientists no longer need to battle with variance, unreliability, physiological irrelevance and long experimental timelines. Instead, scientists can finally focus on the next great advances in human health.
ioCells are for research use only.
ioWild Type Cells
ioWild Type Cells are defined, easy-to-use, functional iPSC-derived human cells from a healthy donor background that are ready for fundamental research and drug discovery experimentation within days.
ioDisease Model Cells
ioDisease Model Cells are ioWild Type Cells engineered to contain disease-relevant mutations. ioDisease Model Cells and ioWild Type Cells form an isogenic pair allowing scientists to make true comparisons.
CRISPR-Ready ioCells
CRISPR-Ready ioCells are human iPSC-derived cells constitutively expressing Cas9 nuclease for rapid gene knockout generation.
ioTracker Cells
ioTracker Cells are human iPSC-derived cells constitutively expressing a fluorescent protein for easy visualisation, tracking, and isolation of human cells in live-cell imaging assays.
Consistent
Our platform ensures consistency between every batch of cells, overcoming the challenge of data reproducibility.
Cost-effective
ioCells generate quality data at industry leading seeding densities. You can do more with every vial as every well saves you money.
Defined
Every ioCell has its identity characterised by ICC, RT-qPCR and RNA-Seq at minimum.
Easy-to-use
ioCells are delivered cryopreserved and require a simple protocol using an open-source medium to get started.
Quick
Deterministically programmed cells mature rapidly, meaning cells are ready for experimentation and data gathering within days post-revival.
Scalable
With opti-ox technology we can make billions of consistently programmed cells, surpassing the demands of industrial workflows.
Dr Marijn Vlaming
Head of Biology - Beerse & Leiden | Charles River
Dr Mariangela Iovino
Senior Group Leader | Biology Discovery | Charles River
Rodney A. Bowling Jr, PhD
Co-Founder & Chief Scientific Officer | Everlum Bio
Every ioCell is powered by opti-ox.
Using opti-ox, populations of stem cells are precisely and consistently programmed into a chosen cell identity. Each vial of ioCells contains a defined and highly characterised population of iPSC-derived human cells that are ready for quality data production in a matter of days. Their high lot-to-lot consistency provides a reliable cell model that enables scientists to conduct repeatable and scalable experiments in drug discovery and disease research.
Thomas Moreau, PhD | VP Cell Programming Research | 不良研究所
Ann Byrne, MSc | Regional Sales Manager, APAC | 不良研究所
Gianmarco Mastrogiovanni, PhD | Principle Scientist - Cell Type Development | 不良研究所
Jack Gowen, MSc | Scientist, QC and GMP, Analytical Development | 不良研究所
Charlotte Durham, BSc | Operational Quality Manager | 不良研究所
Luke Foulser, MSc | Field Applications Scientist | 不良研究所
Austin Passaro, PhD | Global Product Manager MEA | Axion Biosystems
Marius Wernig, Professor | Departments of Pathology and Chemical, and Systems Biology and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine | Stanford University
Samantha Morris, PhD | Principle Investigator | Brigham and Women鈥檚 Hospital and Harvard Medical School, Department of Systems Biology
Thomas Moreau, PhD | Vice President of Cell Programming Research | 不良研究所
Ben Bar-Sadeh, PhD | Senior Scientist | Anima Biotech
Tom Brown | Senior Product Manager | 不良研究所
Sebastian Fiedler, PhD | Applications Marketing Manager | 不良研究所
Malika Bsibsi, PhD | Research Leader Neuroscience | Charles River Laboratories
Austin Passaro, PhD | Global Product Manager MEA | Axion Biosystems
Cicely Schramm, PhD | Head of Biology Imaging | Sartorius
Antonella Santuccione Chadha, MD | Founder and CEO | Women鈥檚 Brain Foundation
Melanie Einsiedler, PhD | Scientific Contributor | Women鈥檚 Brain Foundation
Rebecca Northeast, PhD | Senior Product Manager | 不良研究所
Stephen Ferguson, PhD | Investigator, Mechanistic Toxicology | Division of Translational Toxicology (DTT) | National Institute of Environmental Health Sciences
Tom Brown | Senior Product Manager | 不良研究所
Professor Luke Gilbert | Associate Professor | University of California San Francisco
Sejla Salic-Hainzl | Vice President of Research and Development | 不良研究所
Bernard, et al
不良研究所
2024
Dr Brian Gill, MD | Assistant Professor of Neurological Surgery| Columbia University Irving Medical Center
Dr Tony Oosterveen | Principal Scientist and CNS Lead, Neurobiology | 不良研究所
Luke Foulser | Scientist | 不良研究所
Tom Brown | Senior Product Manager | 不良研究所
Marcos Herrera Vaquero, PhD | Senior Scientist | 不良研究所Vaquero, et al
不良研究所
2023
Emmanouil Metzakopian | Vice President, Research and Development | 不良研究所
Javier Conde-Vancells | Director Product Management | 不良研究所
Dr Marieke Aarts | Principal Scientist | Bi/ond
Amanda Turner | Senior Product Manager | 不良研究所
Dr Mitchell Han
Bi/ond
2023
V2
不良研究所
2023
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | 不良研究所
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | 不良研究所
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | 不良研究所
Mark Kotter | CEO and founder | 不良研究所
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | 不良研究所
Rodney A. Bowling Jr., Ph.D. | Chief Scientific Officer | Everlum Bio
Malathi Raman Ph.D. | Senior Product Manager | 不良研究所
Oosterveen, et al
不良研究所
2022
Ritsma, et al
Charles River Laboratories & 不良研究所
2022
Raman, et al
不良研究所
2022
Dr Matthias Pawlowski | Head, Dementia-Sensitive Hospital | University of M眉nster
Dr Malathi Raman | Senior Product Manager | 不良研究所
不良研究所
Dr Emma V Jones | Senior Scientist | Medicines Discovery Catapult
Dr Tony Oosterveen | Senior Scientist | 不良研究所
Dr Deepak Srivastava | King鈥檚 College London
Dr Mariangela Iovino | Group Leader | Charles River
Dr Tony Oosterveen | Senior Scientist | 不良研究所
Dr Will Bernard | Director of Cell Type Development | 不良研究所
Dr Luke Flatt | Senior Scientist | Charles River Laboratories
Dr Will Bernard | Senior Scientist | 不良研究所
Dr Marijn Vlaming | Head of Biology, et al.
Charles River & 不良研究所
Dr Marijn Vlaming | Head of Biology
Charles River
Dr Alex Davenport | Senior Scientist | 不良研究所
Talk at ELRIG Cell & Gene Therapy
2021
Kam Dhaliwal | SVP Strategic Alliances | 不良研究所
Talk at ELRIG CRISPR in Drug Discovery
Kings College London & 不良研究所
Panel discussion at Oxford Global Discovery UK
Lachize, et al
Courtesy of Charles River Laboratories
2020
Kam Dhaliwal | SVP Strategic Alliances | 不良研究所
Dr Thomas Moreau | Head of Research | 不良研究所
Talk at ELRIG Drug Discovery Digital
不良研究所 (chair) | AstraZeneca | PhoreMost Ltd | Aelian Biotechnology GmbH | Charles River
Panel discussion at ELRIG Drug Discovery Digital
Dr Shushant Jain | Group Leader In Vitro Biology | Charles River
Interview at SLAS
Prof Hagan Bayley | University of Oxford
Dr Mark Kotter | Founder and CEO | 不良研究所